RxDoctor Payments Data

Jihad Younes, MD

Allergy & Immunology · Lake Orion, MINPI 1811996218

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.4% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 25.0% of the total.

$5,236in general payments, 2019–2025

Across 244 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$773
  • Sanofi$761
  • Genentech USA, Inc.$208
  • Pfizer$189
  • plus $925 from 12 others

What the payments were for

  • Food & beverage$4,94494%
  • Education$2926%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,236 in reported general payments places this provider in the 65th percentile of 119 allergy & immunology providers in Michigan.

See all allergy & immunology providers in Michigan

Medicare billing

Part B allowed, 2024
$20,784
Medicare patients
59
Services billed
1,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$40,272
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$35,374
Breo ElliptaFluticasone/Vilanterol32$20,007
Spiriva RespimatTiotropium Bromide14$9,798
SymbicortBudesonide/Formoterol Fumarate12$4,644
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,900
Fluticasone Propionate52$1,828
Olopatadine Hcl15$1,760
Albuterol Sulfate HfaAlbuterol Sulfate27$930
Montelukast Sodium29$614
Ipratropium Bromide14$417
Prednisone38$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,071$55,38169 claims
Boehringer IngelheimSpiriva Respimat$117$9,79814 claims
AstraZenecaSymbicort$1,310$4,64412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 119 allergy & immunology providers in Michigan.

Other allergy & immunology in Lake Orion

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →